Characterize the real-world management of and outcomes for children with epilepsy receiving rescue medication for prolonged acute convulsive seizures (PACS) in the community.
INTRODUCTION
Most seizures experienced by children with epilepsy stop spontaneously within 5 minutes, but prolonged seizures lasting longer than 5 minutes are likely to progress to status epilepticus without treatment.
(1) Convulsive status epilepticus can cause irreversible neurological damage and death (mortality about 3-5%), and requires early treatment to control seizures and improve outcomes. Randomized controlled studies have shown that benzodiazepine rescue medications terminate seizures when given in the emergency department 
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community. The value of this real-world information about the use of rescue medication, together with the limitations of the study, including recall bias, are discussed.
METHODS

Design
PERFECT-3 was a European, retrospective, observational, survey-based study of the realworld management of PACS from the perspective of patients, caregivers and physicians.
Eligible patients were non-institutionalized children (aged 3-16 years) who had been diagnosed with epilepsy at least 12 months previously, had experienced one or more PACS in the past 12 months, and had one or more current prescriptions for PACS rescue medication.
PACS were defined as clinically registered convulsive seizures lasting longer than 5 minutes.
Patients with pseudoseizures, other nonepileptic events, or febrile convulsions with no diagnosis of epilepsy were excluded from the study.
Ethics and conduct
The study was conducted from July 2013 to May 2014 in accordance with the International Conference on Harmonisation of Good Clinical Practice, the Declaration of Helsinki, and local ethical and legal requirements for non-interventional studies (where applicable).
Patients were identified by consecutive sampling of eligible children attending their usual centre visits. After obtaining informed consent from parents/guardians and assent from children aged 7-16 years, physicians registered eligible patients from 20 specialist paediatric neurology centres and paediatric departments in Germany, Italy, Spain, and the UK. The planned sample size was 20 patients from each study centre; a nationally representative patient sample was sought from each participating country. The web-based system allowed enrollment of patients only if the quota for their age group (3-6 years, 7-12 years, and 13-16 years at study enrollment) in each country had not been filled.
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Assessments
Demographic, medical history, and treatment information, including prescribed PACS rescue medications, were extracted from patients' medical records and entered into a web-based system by site staff. Web-based questionnaires were completed by investigators (13 questions) and parents/guardians (110 questions) to document their experience of caring for children with PACS in the community. Epilepsy aetiology responses from investigator questionnaires were classified according to the latest terminology recommended by the International League Against Epilepsy (ILAE).
(10) The recall period for questions in the survey was up to 12 months. In the case of missing responses, parents/guardians and investigators were prompted by email reminders through the web-based system to complete all questions. All web-based questionnaires were completed at the convenience of the parent/guardian and were available from any computer with internet access. Access to the relevant questionnaire was obtained using a key and URL provided by the study centre. Other measures included in this study were patient/proxy questionnaires and quality-of-life instruments (results to be reported in a subsequent publication).
Data analysis
This observational study had no pre-specified primary endpoint. Analyses were performed for all enrolled patients with survey data entered into the web-based system; incomplete questionnaires were not analyzed. The duration of seizures both without rescue medication and when rescue medication was given was obtained from parents' responses to two survey questions: 'When your child experiences a prolonged seizure, on average how long does it last when no rescue medication has been given?' and 'When your child experiences a prolonged seizure, on average how long does it last after rescue medication has been given?'.
Responses were based on parental recollections from the previous 12 months. The available 
RESULTS
Patients
Clinical data were extracted from medical records for all 286 enrolled children (Germany, n = 92; Italy, n = 75; Spain, n = 77; UK, n = 42) ( Table 1 ). Questionnaires were completed by investigators for 281 children and by parents/guardians for 258 children ( 
PACS frequency
At study entry, patients had experienced 1-400 PACS in the past 12 months; 8 patients had experienced more than 200 PACS (Table 1) . A skewed distribution of PACS frequency was observed in the parent survey (Fig. 1A) ; 44.9% of patients had experienced fewer than 2 or 3 PACS in the past 12 months, and 3.9% had experienced several PACS a day (N = 258). A
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skewed distribution of PACS frequency was also observed in medical record extracts (data not shown).
Prescribed rescue medications
Overall, 69.2% of enrolled children had prescriptions for diazepam and 55.9% for midazolam at study entry; some had two (26.6%) or three (2.4%) prescribed rescue medications (Fig. 1B) (N = 286). The formulation was buccal, rectal, or other for 5.1%, 77.3%, and 17.7% of the 198 diazepam prescriptions and 91.3%, 0.6%, and 7.5% of the 160 midazolam prescriptions, respectively. Other rescue medications prescribed included lorazepam and paraldehyde.
Rescue medication prescription patterns differed across countries ( Fig. S.1 ).
Average duration of seizures with and without rescue medication
Parents of 258 of the 286 enrolled patients completed the parent questionnaire. As a result of the training and information they had received, 248/258 (96.1%) of parents felt at least moderately confident about their ability to effectively administer rescue medication.
Information was not collected about care plans for individual patients, including how long parents/carers had been advised to wait before administering rescue medication.
DISCUSSION
This large study in four European countries provides the first real-world data that administration of rescue medication by caregivers in the community is associated with reduced seizure duration among children with epilepsy. Participating children were noninstitutionalized and most experienced PACS despite receiving regular anti-epilepsy therapy.
Their prescribed rescue medications were mainly diazepam (usually rectal) and/or midazolam (usually buccal). Parents reported the average duration of their child's seizures when untreated and when rescue medication was given. Overall, more seizures lasted less than 5 minutes when children received their rescue medication than when they did not.
Furthermore, fewer seizures lasted longer than 20 minutes when children received their rescue medication than when they did not.
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Regardless of seizure location (home/school/elsewhere), about one-quarter of children did not receive the prescribed rescue medication for their most recent PACS, despite parents' reports that most of the children's average seizures were shorter when rescue medication was given than when they were untreated. Furthermore, about one-third of children who received rescue medication did not receive it within 5 minutes and about one-tenth did not receive it within 10 minutes for their most recent PACS. Data were not collected about why rescue medication was not given, or was given only after a certain amount of time. We speculate that the underlying reasons may have been concerns about the safety, tolerability, ease of administration, and social acceptability of the prescribed rescue medication. A lack of caregiver knowledge on patients' treatment plans, including the recommended time before administration of rescue medication after the onset of a seizure, may also explain why rescue medication was not administered at all or was not administered within a specific time interval
for particular seizures. It should also be noted that parental recollections represented their perception of an 'average seizure'. Therefore, data about specific rescue medication for each individual seizure were not collected. Nevertheless, the findings suggest that improved education of parents, school staff, and other caregivers about the importance of early treatment according to the physician's recommendations could benefit children who experience PACS, in all countries and for all rescue medications. This highlights the need for clear and consistent clinical guidelines on community use of PACS rescue medication.
The strengths of this study include the large European population and the collection of realworld data on non-institutionalized children with epilepsy whose PACS are managed by caregivers in the community. However, the limitations of this retrospective observational study should be taken into consideration. The study sites were generally specialized neurology centres, which may treat patients with more severe or frequent seizures than nonspecialist paediatric centres, so the results may not be applicable to general clinical practice.
To limit selection bias, the recruitment process involved consecutive sampling of eligible patients attending their routine centre visit. Gender effects were not investigated in this study, although each country enrolled approximately even numbers of males and females. Eligible patients were required to have had at least one PACS in the 12 months before enrollment, meaning that the study population represented a subset of children with epilepsy. However, the selection criteria allowed recruitment of children with widely ranging disease severity ( A parent of each patient was asked how long their child's seizures lasted on average, both without rescue medication and when rescue medication had been given. Available responses were: 0 to <5, 5 to <10, 10 to <15, 15 to <20, or ≥20 minutes. Grey background shading indicates no change in parent-reported average seizure duration category. Grey text indicates an increase and black text indicates a decrease in the parent-reported average seizure duration category when rescue medication was given compared with when it was not given. prescribed PACS rescue medication(s) at study entry, from medical records.
Other rescue medications were lorazepam (10 patients), paraldehyde (1 patient), and unspecified rescue medication (7 patients). PACS = prolonged acute convulsive seizures. 
